Copyright © 2010 Watson Pharma, Inc.
All rights reserved.
Legal/Copyright Disclaimer Privacy Policy

 

Please note that the product information provided on this website is intended only for residents of the United States.

In IVF-ET cycles—

 

Pregnancy Rates Comparable to IM Progesterone1

 

Study design: Results of a retrospective analysis of 1675 IVF-ET cycles in which women received progesterone for luteal phase support. Patients received Crinone 8% (90 mg QD), progesterone vaginal suppositories (100 mg QD), or IM progesterone (50 mg QD). Progesterone support started on the day after oocyte retrieval and continued through 7–10 weeks in case of pregnancy.

 

Crinone 8% usage more than doubled during this retrospective study

  • Usage increased from 21.7% in the 1st quarter to 50.1% by the 4th quarter
  • Type of progesterone was determined by patient and physician preference

Reference: 1. Alper MM, Penzias AS. Crinone® offers excellent implantation rates in patients undergoing IVF. Paper presented at the 16th Annual Meeting of the European Society for Human Reproduction & Embryology; June 2000; Bologna, Italy. Abstract P-059.

 

Important Safety Information

The most common side effects of CRINONE (progesterone gel) 8% include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain. CRINONE 8% is contraindicated in patients with active, or a history of, thrombophlebitis or thromboembolic disorders, patients who have known sensitivity to CRINONE 8%, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs. Should any of the earliest manifestations of thrombotic disorders occur, the drug should be discontinued immediately. No adequate evidence is available to show that progesterone and progestins are effective in preventing miscarriage in women with a history of recurrent spontaneous pregnancy losses. The pretreatment physical exam should include special reference to breast and pelvic organs as well as a Papanicolaou smear. Nonfunctional causes of breakthrough bleeding should be considered, and for undiagnosed vaginal bleeding, diagnostic measures should be undertaken. Special care should be taken with patients who have conditions that may be influenced by fluid retention, those who have a history of psychic depression, and those with diabetes.